Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael J Brooks is President at Edesa Biotech. OQRO lists 2 transactions filed with the SEC under this name, the latest on May 30, 2026, each linked to the official Form 4.
President
Disclosures on record
2
Companies involved
1
As of the latest filing on , Michael J Brooks reported holding 291,479 shares of Edesa Biotech (EDSA), worth about $551K at the last close of $2 (Nov 16, 2026). In the last 12 months, Michael J Brooks bought $3.1K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Edesa Biotech EDSA | 291,479 | 291K direct | $2 | $551K | May 27, 2026 |
Is this Michael J Brooks’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median −27.3 pts vs S&P 500, beat it 0 of 1 time.
Average −27.3 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Mar 12, 2026 to Mar 12, 2026, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-16 would be worth $326 today ($1K put in); the same in the S&P 500 (SPY): $1.1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Edesa BiotechEDSA
2 disclosures · Mar 2026 – May 2026 · 1 bought
May 27, 202665Kdisclosed May 30
DetailsOfficial recordFeb 26, 2026Bought~$3.1Kdisclosed Mar 12
DetailsOfficial recordMichael J Brooks bought shares on the open market in 2020, 2021, 2022 and 2026.
Michael J Brooks reported 12 open-market purchases and 0 sales since 2020; purchases in 4 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $3.1K1×1 trade | — |
| 2022 | $26K6×6 trades | — |
| 2021 | $41K2×2 trades | — |
| 2020 | $15K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 27, 2026, Michael J Brooks reported holding 291,479 shares of Edesa Biotech (EDSA). At the last close of $2 on Nov 16, 2026, that is about $551K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Michael J Brooks reported 1 open-market purchase worth $3.1K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Michael J Brooks bought shares on the open market in 2020, 2021, 2022 and 2026.
In SEC filings since 2020: the latest open-market purchase is from 2026; no open-market sale is on record.
Edesa Biotech (EDSA), from 2020 to 2026: 12 purchases and 0 sales.
Michael J Brooks reported 12 open-market purchases and 0 sales here, 2020 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.